Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew P Morrow

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Nature Communications|February 12, 2025
DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107Matthew P Morrow, Elisabeth Gillespie, Albert Sylvester, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|January 29, 2026
A Phase Ib, Placebo-controlled Randomized Clinical Trial of the Ebolavirus DNA Vaccine Candidate INO-4201 Followed by Electroporation as Booster Vaccination in Healthy, rVSVΔG-ZEBOV-GP-primed Volunteers (Boost-EBOV)Angela Huttner, Marc-Antoine de La Vega, Cristina Boehm-Bosmani, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 26, 2020
CD8<sup>+</sup> T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated AntigensNeal D Shore, Matthew P Morrow, Trevor McMullan, et al.
Lancet (London, England)|September 21, 2015
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trialCornelia L Trimble, Matthew P Morrow, Kimberly A Kraynyak, et al.
Frontiers in Immunology|November 10, 2025
Safety, tolerability, and immunogenicity of INO-4500, a synthetic DNA-based vaccine against Lassa virus, in a phase 1b clinical trial in healthy Ghanaian adultsKwadwo Ansah Koram, Kathleen A Walker, Bonaventure Orizu, et al.
JCI Insight|May 22, 2020
Robust antibody and cellular responses induced by DNA-only vaccination for HIVStephen C De Rosa, Srilatha Edupuganti, Yunda Huang, et al.
Vaccines|December 10, 2020
Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GP<sup>®</sup> DNA Vaccine and IL-12 Is Safe, Tolerable, Acceptable in Healthy AdultsSrilatha Edupuganti, Stephen C De Rosa, Marnie Elizaga, et al.
NPJ Vaccines|December 22, 2017
<i>In vivo</i> protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccineKaruppiah Muthumani, Bryan D Griffin, Sangya Agarwal, et al.
The Journal of Infectious Diseases|January 26, 2022
SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label TrialKimberly A Kraynyak, Elliott Blackwood, Joseph Agnes, et al.
Eclinicalmedicine|January 4, 2021
Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trialPablo Tebas, ShuPing Yang, Jean D Boyer, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Nature Communications|February 12, 2025
DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107Matthew P Morrow, Elisabeth Gillespie, Albert Sylvester, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|January 29, 2026
A Phase Ib, Placebo-controlled Randomized Clinical Trial of the Ebolavirus DNA Vaccine Candidate INO-4201 Followed by Electroporation as Booster Vaccination in Healthy, rVSVΔG-ZEBOV-GP-primed Volunteers (Boost-EBOV)Angela Huttner, Marc-Antoine de La Vega, Cristina Boehm-Bosmani, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 26, 2020
CD8<sup>+</sup> T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated AntigensNeal D Shore, Matthew P Morrow, Trevor McMullan, et al.
Lancet (London, England)|September 21, 2015
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trialCornelia L Trimble, Matthew P Morrow, Kimberly A Kraynyak, et al.
Frontiers in Immunology|November 10, 2025
Safety, tolerability, and immunogenicity of INO-4500, a synthetic DNA-based vaccine against Lassa virus, in a phase 1b clinical trial in healthy Ghanaian adultsKwadwo Ansah Koram, Kathleen A Walker, Bonaventure Orizu, et al.
JCI Insight|May 22, 2020
Robust antibody and cellular responses induced by DNA-only vaccination for HIVStephen C De Rosa, Srilatha Edupuganti, Yunda Huang, et al.
Vaccines|December 10, 2020
Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GP<sup>®</sup> DNA Vaccine and IL-12 Is Safe, Tolerable, Acceptable in Healthy AdultsSrilatha Edupuganti, Stephen C De Rosa, Marnie Elizaga, et al.
NPJ Vaccines|December 22, 2017
<i>In vivo</i> protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccineKaruppiah Muthumani, Bryan D Griffin, Sangya Agarwal, et al.
The Journal of Infectious Diseases|January 26, 2022
SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label TrialKimberly A Kraynyak, Elliott Blackwood, Joseph Agnes, et al.
Eclinicalmedicine|January 4, 2021
Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trialPablo Tebas, ShuPing Yang, Jean D Boyer, et al.
Pageof 5